City Therapeutics raises $99.5 million to advance three RNAi drug candidates
read at Endpoints ↗DealPositive
City Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing.
The capital will be used to move its first three RNAi candidates into clinical development and to broaden the company’s pipeline beyond liver‑focused targets.
The funding round underscores investor confidence in the company’s technology platform and its potential to deliver new RNAi therapies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “City Therapeutics gets $99M to gather data on three RNAi medicines”
read at Endpoints ↗89 words · retrieved Jun 8
comments(0)
5-min edit window · permanent after that